Article Text

PDF
THU0132 Points to Consider for use of Antirheumatic Drugs Before and During Pregnancy and Lactation: Progress of a Eular Task Force
  1. A.C. Skorpen1,
  2. M. Østensen2
  3. on behalf of EULAR task force Points to consider for use of antirheumatic drugs before/during pregnancy and lactation
  1. 1Rheumatology, Hospital, Ålesund
  2. 2Rheumatology, University, Trondheim, Norway

Abstract

Background Guidelines and recommendations regarding risk and safety of antirheumatic drugs during pregnancy and lactation from professional societies vary considerable between countries

Objectives A EULAR task force was established to reach a consensus on antirheumatic drugs during pregnancy and lactation.

Methods A systematic search of the literature for publications on classic antirheumatic and biological drugs during pregnancy and lactation was performed. A statement in regard to pregnancy and lactation was made and the strength of evidence for “points to consider” was based on customary scoring systems. Delphi voting was applied to assess the level of agreement between task force members.

Results The systematic literature search for the period 2006-2015 retrieves an increasing documentation on the use of antirheumatic drugs in pregnant women, and the outcome of their pregnancies. This is particularly apparent regarding the TNF-inhibitors (Table 1). However, only few reports are prospective studies, and include a control group. Publications on drugs used during breastfeeding are very rare and lack completely for several antirheumatic drugs.

Table 1.

Type and number of publications on pregnancy exposure to different TNFalpha inhibitors

Conclusions The international consensus of ‘Points to consider’ will support the clinicians in counseling patients desiring children, and will meet the needs of 60-80% of patients with rheumatic diseases planning pregnancy who seek information on medication from health professionals and the internet.

References

  1. Østensen M, Khamashta MA, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8: 209

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.